Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | The role of CAR-T therapy in high-risk LBCL in the first and second-line settings

Alberto Mussetti • 28 Oct 2022
COSTEM 2022
B-Cell Lymphoma Non-Hodgkin Lymphoma CAR-T

Alberto Mussetti, MD, Institut Catala d’Oncologia Hospitalet, Barcelona, Spain, describes the merits and challenges of using anti-CD19 CAR-T therapy as a first- and second-line therapy to treat patients with high-risk large B-cell lymphoma (LBCL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alberto Mussetti

2:25
Comparing the outcomes of patients with LBCL receiving alloSCT versus anti-CD19 CAR-T therapy
Alberto Mussetti • 12 Dec 2022
2:47
Using artificial intelligence to estimate overall mortality and non-relapse mortality after alloSCT
Alberto Mussetti • 12 Dec 2022
0:44
The role of alloSCT for R/R LBCL in the era of CAR-T therapy
Alberto Mussetti • 12 Dec 2022
1:59
The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence
Alberto Mussetti • 28 Oct 2022

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals